Investigation on the characteristics of patients with overlap syndrome of bronchial asthma and chronic obstructive pulmonary disease and the corresponding treatment strategy
LING Wen-shan HOU Xian-yun HUANG Shu-hua
Department of Internal Medicine,the Sixth People′s Hospital of Nansha District in Guangzhou City of Guangdong Province,Guangzhou511470,China
Abstract:Objective To investigate the characteristics of the patients with overlap syndrome of bronchial asthma and chronic obstructive pulmonary disease(ACOS)in order to make the best choice for the treatment of ACOS patients. Methods A total of 82 patients with ACOS(ACOS group)treated in the Sixth People′s Hospital of Nansha District in Guangzhou City from December 2015 to August 2016 were selected.they were treated by Montelukast 10 mg each time, once per day.The drug should be taken before sleep and course of treatment was lasted for 12 weeks.The clinical data from the other two groups of 100 patients with chronic obstructive pulmonary disease(COPD group)and 85 asthmatic patients(asthma group)in the same period were retrospectively analyzed.The general condition,pulmonary function,proportion of induced sputum cell eosinophil granulocyte(EOS),fractional exhaled nitric oxide(FENO),St.George respiratory questionnaire(SGRQ)assessment,and frequency of acute exacerbations within 2 years were investigated and analyzed among three groups.Results There were no statistical differences in gender,ethnics,educational background,and health care(P>0.05).In the ACOS group,average age,proportion of frequent lower respiratory tract infection in children, yearly decreasing level of forced expiratory volume in one second(FEV1)within 2 years,SGRQ score,and frequency of acute exacerbations within 2 years were much higher than those in the COPD group and asthma group,which were displayed statistical differences(P<0.05).In the ACOSgroup,the indexes of body mass index and diffusion function DLCO/VA(%)were both greatly lower in comparison with those in the COPD group and asthma group with statistical differences(P<0.05).For ACOS patients,the levels of FEV1, FEV1%,peak expiratory flow(PEF),and PEF%were all much higher compared with those before treatment with statistical differences(P<0.05).Conclusion In clinic,pulmonary function decreases fast in ACOS patients,quality of life-related with health is poor,and is inclined to repeated acute exacerbations.Montelukast therapy can effectively enhance pulmonary function in ACOS patients and provide a strong basis for clinical research.
凌文珊;侯宪云;黄树华. 支气管哮喘慢性阻塞性肺病重叠综合征的患病人群特征调查及应对治疗策略[J]. 中国当代医药, 2017, 24(7): 166-169.
LING Wen-shan;HOU Xian-yun;HUANG Shu-hua. Investigation on the characteristics of patients with overlap syndrome of bronchial asthma and chronic obstructive pulmonary disease and the corresponding treatment strategy. 中国当代医药, 2017, 24(7): 166-169.
Pin I,Gibson PG,Kolendowicz R,et al.Use of induced sputum cell counts to investigate airway inflammation in asthma[J].Thorax,1992,47(1):25-29.
[15]
American Thoracic Society.Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children 1999[J].Am J Respir Crit Care Med,1999,160(6):2104-2117.
[16]
de Marco R,Pesce G,Marcon A,et al.The coexistence of asthma and chronic obstructive pulmonary disease(COPD):prevalence and risk factors in young,middle-aged and elderly people from the general population[J].PLoS One,2013,8(5):e62985.
[18]
Chaudhuri R,Livingston E,McMahon AD,et al.Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma[J].Am J Respir Crit Care Med,2003,168(11):1308-1311.